FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

PepsiCo Inc.

PEPConsumer Staples

Generated Aug 19, 2026, 11:17 PM UTC

analytical score -16

PEP (PepsiCo Inc.) analytical snapshot. Revenue grew +2.3% YoY to $93.92B. 5-year revenue CAGR +3.4%; 10y CAGR +4.6%. Net margin at 8.77% (contracting ▼). Market cap $194.61B at $142.58 per share. Trailing P/E 23.76, P/S 2.07, P/B 8.81. EV/Operating income ≈ 20.06 (EV $230.71B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -16 (data confidence 83%). Descriptive analytics from public filings — not investment advice.

Market cap
$194.61B
1.36B shares
Price
$142.58
NMS
P/E (ttm)
23.76
Revenue (FY)
$93.92B
YoY +2.3%
Net margin
8.77%
▼ 1.54pp
Free cash flow
$7.67B
8.17% margin
Risk level
Elevated

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 30Improving
80% conf

Latest annual report (10-K) filed Feb 3, 2026. Latest quarterly report (10-Q) filed Jul 9, 2026. 16 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 3, 2026.
  • Latest quarterly report (10-Q) filed Jul 9, 2026.
  • 16 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference PepsiCo Inc.; broad institutional reporting.
  • Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
  • 19 recent 13D activist/beneficial-ownership filings — potential catalyst.
  • 1 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 3, 2026
Annual report
Latest 10-Q
Jul 9, 2026
8-K (recent)
16
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
19
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRMay 15, 2003
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRFeb 12, 2004
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRAug 9, 2002
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRMay 11, 2004
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRFeb 11, 2003
Recent 8-K material events
DateFormDescription
Jul 9, 20268-K8-K
May 22, 20268-KFORM 8-K
May 8, 20268-K8-K
Apr 16, 20268-K8-K
Feb 11, 20268-KFORM 8-K
Feb 3, 20268-K8-K
Dec 15, 20258-K8-K
Dec 8, 20258-K8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score 3Stable
70% conf

1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.

  • Operating cash flow exceeds net income: OCF is 1.47x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
Revenue
$93.92B
+2.3% YoY
Gross profit
$50.86B
+1.5% YoY
Operating income
$11.50B
-10.8% YoY
Net income
$8.24B
-14.0% YoY
Operating cash flow
$12.09B
-3.4% YoY
Capex
$4.42B
-17.0% YoY
Total assets
$107.40B
+8.0% YoY
Total liabilities
$86.85B
+6.8% YoY
Filing quality score
69/100
2 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$91.85B$93.92B$2.07B+2.3%
Gross profit$50.11B$50.86B$749.0M+1.5%
Operating income$12.89B$11.50B$-1.39B-10.8%
Net income$9.58B$8.24B$-1.34B-14.0%
Operating cash flow$12.51B$12.09B$-420.0M-3.4%
Capex$5.32B$4.42B$-903.0M-17.0%
Total assets$99.47B$107.40B$7.93B+8.0%
Total liabilities$81.30B$86.85B$5.56B+6.8%
Long-term debt$41.23B$46.35B$5.12B+12.4%
Cash & equivalents$8.51B$9.16B$654.0M+7.7%
Stockholders equity$18.04B$20.41B$2.37B+13.1%
Inventory$5.31B$5.84B$539.0M+10.2%
R&D expense$813.0M$839.0M$26.0M+3.2%
SG&A expense$37.19B$37.37B$178.0M+0.5%
Interest expense$919.0M$1.12B$202.0M+22.0%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedProceedsFromSaleOfAvailableForSaleSecuritiesDebt, SegmentExpenditureAdditionToLongLivedAssets
RemovedAccountsPayableCurrent, AccountsReceivableGrossCurrent, AccruedEmployeeBenefitsCurrent, AdvertisingExpense, AmortizationOfIntangibleAssets, AssetImpairmentCharges, CapitalizedComputerSoftwareAmortization1, CapitalizedComputerSoftwareNet, CashCollateralForBorrowedSecurities, CommonStockCapitalSharesReservedForFutureIssuance
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Impairment chargemedium56Ongoing
Restructuringmedium510Ongoing
Off-balance sheet arrangementsmedium58Ongoing
Related party transactionslow50NEW
Filing signal breakdown
Red flags: 0
Positive: 1
Watch: 0
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score -15Stable
80% conf

Revenue grew +2.3% YoY to $93.92B. 5-year revenue CAGR +3.4%; 10y CAGR +4.6%. Net margin at 8.77% (contracting ▼).

  • Revenue grew +2.3% YoY to $93.92B.
  • 5-year revenue CAGR +3.4%; 10y CAGR +4.6%.
  • Net margin at 8.77% (contracting ▼).
  • Return on equity 40.38%, ROA 7.67%, ROIC 17.22%.
  • Gross margin 54.15%, operating margin 12.24%.
  • Free cash flow margin 8.17% ($7.67B).
  • Net income down ▼ +14.0% YoY.
  • Debt/equity 2.10, current ratio 0.93, net debt $36.10B.
  • Asset turnover 0.84 — capital efficiency.
Revenue (FY)
$93.92B
YoY +2.3%
Net margin
8.77%
▼ 1.54pp
ROE
40.38%
ROA 7.67%
ROIC
17.22%
EPS (diluted)
$6.00
FY2025
Free cash flow
$7.67B
8.17% margin
Debt / equity
2.10
Cash $10.25B
Current ratio
0.93
Equity $22.10B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$91.85B+0.4%54.5514.0310.43$7.19B53.09
2025$93.92B+2.3%54.1512.248.77$7.67B40.38
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Sep 7, 2024$23.32B——12.56%
Mar 22, 2025$17.92B—-23.2%10.23%
Jun 14, 2025$22.73B—+26.8%5.56%
Sep 6, 2025$23.94B—+5.3%10.87%
Mar 21, 2026$19.44B—-18.8%11.97%
Jun 13, 2026$24.18B—+24.4%12.33%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -60Deteriorating
95% conf

Market cap $194.61B at $142.58 per share. Trailing P/E 23.76, P/S 2.07, P/B 8.81. EV/Operating income ≈ 20.06 (EV $230.71B).

  • Market cap $194.61B at $142.58 per share.
Market cap
$194.61B
1.36B shares
P/E (ttm)
23.76
P/S
2.07
P/B
8.81
EV
$230.71B
Intrinsic (DCF)
$85.14
-40.3% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score 0Stable
85% conf

Price $142.58 — downtrend (below 200-DMA); 1-month momentum positive. RSI(14) 58.67.

  • Price $142.58 — downtrend (below 200-DMA); 1-month momentum positive.
Price
$142.58
NMS
RSI(14)
58.67
50-DMA
$140.08
200-DMA
$148.97
Volatility (ann.)
21.24%
52w range
$133.73–$171.48
-16.9% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score -30Deteriorating
90% conf

Composite risk Elevated. Leverage debt/equity 2.10 (high). Liquidity current ratio 0.93 (stretched).

  • Composite risk: Elevated.
Risk level
Elevated
Debt / equity
2.10
Current ratio
0.93
Margin stdev
2.61pp
Cash / assets
9.14%
Liab / assets
80.15%
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite -16

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. PepsiCo Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Market regime: Risk-on · Supportive..

Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How PEP stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM19Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
HCA Healthcare HCA9Neutral
Gilead Sciences GILD8Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG7Neutral
Coca-Cola Co. KO6Neutral
Zoetis Inc. ZTS6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Illumina Inc. ILMN0Neutral
Colgate-Palmolive CL-2Neutral
Vertex Pharmaceuticals VRTX-2Neutral
AbbVie Inc. ABBV-5Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-12Neutral
Costco Wholesale COST-14Neutral
Walmart Inc. WMT-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP● you-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral